Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office ATTY, DOCKET NO. P31855C3

PRED. SERIAL NO. 10/346,947

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**APPLICANT** 

Buckingham et al.

PRED. GROUP 1614

(Use several sheets if necessary)

PRED. FILING DATE 17 January 2003

**U.S. PATENT DOCUMENTS** 

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	4,895,862	1/23/90	Alessi et al.	514	360	
	AB	5,068,342	11/26/91	Zask et al.	548	183	

FOREIGN PATENT DOCUMENTS

	Document	Date	Country	Class	Subclass		
	Number					Yes	No
AC	EP 0 749 751	12/1996	EPO				
AD	WO 93/03724	03/1993	PCT				
AE	WO 98/36755	8/1998	PCT				
AF	EP 0 861 666	09/1998	EPO				
AG	WO 95/21608	08/1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AH Donnelly et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and New Pharmacological Approaches to Metabolism", Br. J. Clin Pharm., 37: 311-320 (1994).  AI Jackson et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes", Diabetes, 36: 632-640 (1987).  AJ G. Williams, "Management of Non-Insulin-Dependent Diabetes Mellitus", The Lancet, 395-100 (1994).  AK Kelley et al., "Troglitazone", Current Opin. Endocrinol. & Diabetes, 5(2): 90-96 (1998).  AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2) (225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
AI Jackson et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes", Diabetes, 36: 632-640 (1987).  AJ G. Williams, "Management of Non-Insulin-Dependent Diabetes Mellitus", The Lancet, 3 95-100 (1994).  AK Kelley et al., "Troglitazone", Current Opin. Endocrinol. & Diabetes, 5(2): 90-96 (1998).  AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2 225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
Diabetes, 36: 632-640 (1987).  AJ G. Williams, "Management of Non-Insulin-Dependent Diabetes Mellitus", The Lancet, 3 95-100 (1994).  AK Kelley et al., "Troglitazone", Current Opin. Endocrinol. & Diabetes, 5(2): 90-96 (1998).  AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2 225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
95-100 (1994).  AK Kelley et al., "Troglitazone", Current Opin. Endocrinol. & Diabetes, 5(2): 90-96 (1998).  AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2): 225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
AL Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2 225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
225-236 (XP002080821).  AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Achievements and Future Developments". <i>Drugs</i> , <u>54(3)</u> : 355-368 (1997).
Achievements and Future Developments". Drugs, 54(3): 355-368 (1997).
AN Iwamoto et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone". <i>Diabetic Med.</i> , 13(4): 365-370 (1996).
AO K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Developmen <i>J. Japan Diabetes Sci.</i> , 3(S1): 962-973 (1990).
AP N. Hotta, "How to Select and Use Oral Hypoglycemic Agents". <i>Chronic Dis.</i> , <u>6(1)</u> : 1-9 (1995).
AQ H. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , 17(12): 1542-1544 (1994).
AR Lehmann et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxi Proliferator-Activated Receptor γ (PPARγ)". J. Biol. Chem., 270: 12953-12956 (1995).
AS Hofmann et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensiting Diabetes Care, 15(8): 1075-1078 (1992).
EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant. n:\kls\cases\p31855c3\pto 1449 form.doc